Hi-Tech Pharmacal Receives Approval for Ciclopirox Topical Solution
Posted on: Wednesday, 19 September 2007, 09:02 CDT
Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that the US Food and Drug Administration (FDA) has granted final approval to the Company's Abbreviated New Drug Application (ANDA) for Ciclopirox topical solution, 8%. Hi-Tech's Ciclopirox topical solution is the generic equivalent of Dermik Laboratories' nail fungus treatment Penlac(R) topical solution, 8%, which had sales of $87 million in 2006 based on IMS sales data.
Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and OTC products for the general healthcare industry. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company's Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.
Forward-looking statements (statements which are not historical facts) in this press release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward looking statements which speak only as of the date made. Hi-Tech is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Business Wire
Related Articles
- FDA approves Pennsaid(R) Topical Solution
- First Uranium doubles gold production capacity at Mine Waste Solutions operation in South Africa
- Study Shows Nonprescription LCD Topical Solution is More Effective than Prescription-Strength Calcipotriol Cream for Moderate Plaque Psoriasis
- Hi-Tech Pharmacal Receives Tentative Approval for Calcipotriene Topical Solution
- Local.Com to Showcase New Online Advertising Products at Ad:Tech New York
- Altiris(R) Software Virtualization Solution(TM) Wins Best New Product Award at TechEd 2006
- Bernanke Says Fed Policy Must Be Forward-looking
- Westinghouse Lauds Progress Energy for Proactive, Forward-Looking Approach to Nuclear Fleet Expansion
- Fullscope Partners With Microsoft at the 2005 FSA Suppliers Expo & Conference As Fullscope Announces the Second Release of Their High Tech Industry Solution for Axapta
User Comments (0)

RSS Feeds